Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours

European Journal of Cancer

Volumn 55, Issue , 2016, Pages 122-130

  Rowland, Andrew ^a   Dias, Mafalda M ^a,b   Wiese, Michael D ^b   Kichenadasse, Ganessan ^a   McKinnon, Ross A ^a   Karapetis, Christos S ^a   Sorich, Michael J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

anti EGFR monoclonal antibodies; KRAS G13D mutation; metastatic colorectal cancer; predictive biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; GENE MUTATION; HUMAN; META ANALYSIS; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM METASTASIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84955282009     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.025     Document Type: Article

References (33)

1. M.J. Sorich, M.D. Wiese, A. Rowland, and et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials Ann Oncol 26 2015 13 21
2. N.C.C.N. NCCN clinical practice guidelines in oncology Colon Cancer Version 2.2015. National Comprehensive Cancer Network 2014
3. S. Guerrero, I. Casanova, L. Farre, and et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression Cancer Res 60 2000 6750 6756
4. M. Horsch, C.V. Recktenwald, S. Schadler, and et al. Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study Br J Cancer 100 2009 656 662
5. G. Smith, R. Bounds, H. Wolf, and et al. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine Br J Cancer 102 2010 693 703
6. W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
7. S. Misale, R. Yaeger, S. Hobor, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
8. S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio, and et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2007 2643 2648
9. M. Frattini, P. Saletti, E. Romagnani, and et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 2007 1139 1145
10. M. Moroni, S. Veronese, S. Benvenuti, and et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 2005 279 286
11. M. Schirripa, S. Lonardi, C. Cremolini, and et al. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC) J Clin Oncol 32 2014 A3524
12. D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
13. Y. Imamura, T. Morikawa, X. Liao, and et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers Clin Cancer Res. 18 2012 4753 4763
14. W.S. Samowitz, K. Curtin, D. Schaffer, and et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study Cancer Epidemiol Biomarkers Prev 9 2000 1193 1197
15. Q. Feng, L. Liang, L. Ren, and et al. A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases Am J Cancer Res 5 2015 674 688
16. D.P. Modest, S. Stintzing, R.P. Laubender, and et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status Anticancer Drugs 22 2011 913 918
17. V. Bazan, M. Migliavacca, I. Zanna, and et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann Oncol 13 2002 1438 1446
18. M.J. Sorich, and M. Coory Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies Pharmacogenomics J 14 2014 1 5
19. R.M. Simon, S. Paik, and D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Nat Cancer Inst 101 2009 1446 1452
20. S.D. Patterson, N. Cohen, M. Karnoub, and et al. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group Pharmacogenomics 12 2011 939 951
21. T.S. Maughan, R.A. Adams, C.G. Smith, and et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
22. S. Tejpar, I. Celik, M. Schlichting, and et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 2012 3570 3577
23. K.M. Tveit, T. Guren, B. Glimelius, and et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30 2012 1755 1762
24. M. Peeters, J.Y. Douillard, E. Van Cutsem, and et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab J Clin Oncol 31 2013 759 765
25. C.G. Smith, D. Fisher, B. Claes, and et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab Clin Cancer Res 19 2013 4104 4113
26. A. Rowland, M.M. Dias, M.D. Wiese, and et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Br J Cancer 112 2015 1888 1894
27. X. Sun, M. Briel, S.D. Walter, and G.H. Guyatt Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses Br Med J 340 2010 c117
28. P.M. Rothwell Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 2005 176 186
29. D.M. Kent, P.M. Rothwell, J.P. Ioannidis, and et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Trials 11 2010 85
30. D.L. Chan, N. Pavlakis, J. Shapiro, and et al. Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature PLoS One 10 2015 e0135599
31. I. Messner, G. Cadeddu, W. Huckenbeck, and et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines J Cancer Res Clin Oncol 139 2013 201 209
32. S.S. Kumar, T.J. Price, O. Mohyieldin, and et al. KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model Gastrointest Cancer Res - GCR 7 2014 23 26
33. H. Osumi, E. Shinozaki, M. Osako, and et al. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival Mol Clin Oncol 3 2015 1053 1057